Le Lézard
Classified in: Health, Business
Subject: RCN

Crown Laboratories Now Operates Under the Name Revance


NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- Crown Laboratories ("Crown"), a fast-growing global aesthetics and skincare company, announced today that it will operate under the name Revance, effective immediately.

This change marks a significant milestone in the company's strategic transformation following its recent acquisition of Revance Therapeutics, Inc., a biotechnology company known for its cutting edge innovation in aesthetics and therapeutics, which joins Crown's deep roots in science-driven brands for skin health and rejuvenation.

"The transition to the Revance name marks an exciting new chapter for our company, representing the future of our combined portfolio of advanced, science-driven brands that are designed to address the ever-changing needs of patients, clinicians, and consumers worldwide," said Jeff Bedard, CEO of Revance.

Revance was chosen as the name that best represents the newly combined company mission to revolutionize the aesthetics and skincare industry through science-based, innovative products.

Bedard continued, "By uniting our complementary market-leading products and incredibly talented teams under one powerful brand, we are strengthening our unique position in the marketplace and unlocking exciting new opportunities for growth. Importantly, our dedication to excellence, innovation, and serving our customers remains unchanged.  We look forward to continuing to execute on our successful integration and go-forward strategy, as we aim to become a global leader in injectables, skin quality and skincare solutions."

About Revance

Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life.  With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments.

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com.

SOURCE Crown Laboratories, Inc.


These press releases may also interest you

at 00:25
Desentum Reports Strong Safety and Immunological Data From Phase 1 Clinical Study With Investigational Birch Pollen Allergy Vaccine DM-101PX
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well...

at 00:17
Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion
Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams."...

at 00:15
In pancreatic cancer, a race against time
Pancreatic cancer is projected to become the second-deadliest cancer by 2030. By the time it's diagnosed, it's often difficult to treat. So, for both individual patients and the general population, fighting pancreatic cancer can feel like a race...

at 00:05
Curium Announces Approval of Generic DTPA - Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.
Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m Pentetate Injection, often referred to as DTPA (diethylenetriaminepentaacetic acid). Technetium Tc 99m...

1 avr 2025
WELL Health Announces Receipt of MCTO
WELL Health Technologies Corp. ("WELL" or the "Company"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announces that further...

1 avr 2025
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
COSCIENS Biopharma Inc. ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announces further to its news release of...

More news about Health...


News published on and distributed by: